147 related articles for article (PubMed ID: 19874308)
1. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia.
Anoop P; Wotherspoon A; Matutes E
Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308
[No Abstract] [Full Text] [Related]
2. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus reactivation and alemtuzumab therapy.
Iannitto E; Minardi V; Calvaruso G; Mulè A; Ammatuna E; Di Trapani R; Ferraro D; Abbadessa V; Craxí A; Di Stefano R
Eur J Haematol; 2005 Mar; 74(3):254-8. PubMed ID: 15693796
[TBL] [Abstract][Full Text] [Related]
4. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy.
Niscola P; Del Principe MI; Maurillo L; Venditti A; Buccisano F; Piccioni D; Amadori S; Del Poeta G
Leukemia; 2005 Oct; 19(10):1840-1. PubMed ID: 16094417
[No Abstract] [Full Text] [Related]
5. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.
Saadeh CE; Srkalovic G
Pharmacotherapy; 2008 Feb; 28(2):281-4. PubMed ID: 18225973
[TBL] [Abstract][Full Text] [Related]
6. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
Thachil J; Salim R
Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
[No Abstract] [Full Text] [Related]
7. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia.
Ammatuna E; Sarlo C; Ottaviani L; Quaresima M; Buccisano F; Campagna S; Del Principe MI; De Angelis G; Anemona L; Gumenyuk S; Amadori S; Venditti A
Leuk Lymphoma; 2009 May; 50(5):857-8. PubMed ID: 19330655
[No Abstract] [Full Text] [Related]
9. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.
Cheung WW; Tse E; Leung AY; Yuen KY; Kwong YL
Am J Hematol; 2007 Feb; 82(2):108-11. PubMed ID: 17013817
[TBL] [Abstract][Full Text] [Related]
10. A fatal case of alemtuzumab-associated interstitial pneumonitis.
Creelan B; Ferber A
Am J Ther; 2008; 15(1):82-4. PubMed ID: 18223357
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.
Yeo W; Johnson PJ
Hepatology; 2006 Feb; 43(2):209-20. PubMed ID: 16440366
[No Abstract] [Full Text] [Related]
12. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
Martin SI; Marty FM; Fiumara K; Treon SP; Gribben JG; Baden LR
Clin Infect Dis; 2006 Jul; 43(1):16-24. PubMed ID: 16758413
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia.
Dilhuydy MS; Jouary T; Demeaux H; Ravaud A
Br J Haematol; 2007 Jun; 137(6):490. PubMed ID: 17425643
[No Abstract] [Full Text] [Related]
14. Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard?
Goodman M
J Clin Oncol; 2005 Oct; 23(28):7240-1; author reply 7241-2. PubMed ID: 16192616
[No Abstract] [Full Text] [Related]
15. Strategies in the management of alemtuzumab-related side effects.
Osterborg A; Karlsson C; Lundin J; Kimby E; Mellstedt H
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S29-35. PubMed ID: 16720201
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245
[No Abstract] [Full Text] [Related]
17. Coronary ischemia related to alemtuzumab therapy.
Basquiera AL; Berretta AR; García JJ; Palazzo ED
Ann Oncol; 2004 Mar; 15(3):539-40. PubMed ID: 14998865
[No Abstract] [Full Text] [Related]
18. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
19. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
Cortelezzi A; Pasquini MC; Gardellini A; Gianelli U; Bossi A; Reda G; Sarina B; Musto P; Barcellini W; Neri A; Deliliers GL
Leukemia; 2009 Nov; 23(11):2027-33. PubMed ID: 19641526
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab.
Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
[No Abstract] [Full Text] [Related]
[Next] [New Search]